MedTrace Logo

Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.

NCT07609576 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2026-05-27

No results posted yet for this study

Summary

This is a prospective, multicenter, observational cohort study involving patients with hematologic malignancies who are receiving bispecific antibody therapy. The primary objective of this study is to evaluate the incidence, type, and severity of infectious complications in hematologic patients undergoing treatment with bispecific antibodies.

Secondary objectives include identifying risk factors associated with infection, comparing infectious outcomes across different hematologic malignancies and BsAb types, and assessing the impact of infections on overall treatment outcomes.

Conditions

  • Lymphoma Neoplasms
  • Myeloma Multiple
  • Severe Infection
  • CMV Reactivation
  • Biespecific Treatment
  • Biespecific

Sponsors & Collaborators

  • Infanta Leonor University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-14
Primary Completion
2026-06-15
Completion
2026-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07609576 on ClinicalTrials.gov